Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers.
about
Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteersSerum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization.Nasal immunization with Burkholderia multivorans outer membrane proteins and the mucosal adjuvant adamantylamide dipeptide confers efficient protection against experimental lung infections with B. multivorans and B. cenocepaciaAdherence-inhibitory intestinal immunoglobulin a antibody response in baboons elicited by use of a synthetic intranasal lectin-based amebiasis subunit vaccine.Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.Strategies for intranasal delivery of vaccinesNasal immunization with Porphyromonas gingivalis outer membrane protein decreases P. gingivalis-induced atherosclerosis and inflammation in spontaneously hyperlipidemic miceContrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans.Mucosal Vaccine Development Based on Liposome Technology.Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract.Current prospects and future challenges for nasal vaccine delivery.Noninvasive vaccination against infectious diseases.The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune responseAdjuvanted influenza vaccines
P2860
Q24545856-13FCCEE9-373A-4866-AA21-6D2E423639F1Q33853571-F412E299-C43C-4BD7-9BCF-804CD726D6F8Q35913531-EB48D8A9-23A4-4769-86D6-21B786D91223Q35949888-33B74674-A052-4504-9154-DE0DF9A35D5BQ36315607-C0AFBE48-B03E-46F4-9715-D1AF2ABCF406Q36514771-30EAAAD4-4E90-4AA5-A8CD-B89389CFBD69Q36747201-01496343-3B83-41DE-B6E6-A7A3FD5183EEQ37423256-48755B8D-709C-4BF6-A1E5-720E49F55AECQ37581129-D351A178-4CCF-4EEE-B3EC-EDD0F9DCC623Q38320741-7E456FA3-5EC4-42A7-8770-8C8B291F46E4Q38784950-6EAD76D7-27C1-4FDF-95C4-98700ABC7A67Q52602778-12B8FC8E-E9D1-4424-8B67-32A3AA8CC7FAQ56994857-2487A8D7-2C55-4AD4-BDDA-A7F326F89D41Q57094841-5DFCFA2C-85AB-415D-BAB6-260AD3919EB8
P2860
Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Phase 1 evaluation of intranas ...... ile toxin in adult volunteers.
@ast
Phase 1 evaluation of intranas ...... ile toxin in adult volunteers.
@en
type
label
Phase 1 evaluation of intranas ...... ile toxin in adult volunteers.
@ast
Phase 1 evaluation of intranas ...... ile toxin in adult volunteers.
@en
prefLabel
Phase 1 evaluation of intranas ...... ile toxin in adult volunteers.
@ast
Phase 1 evaluation of intranas ...... ile toxin in adult volunteers.
@en
P2093
P2860
P1433
P1476
Phase 1 evaluation of intranas ...... ile toxin in adult volunteers.
@en
P2093
P2860
P304
P577
1999-09-01T00:00:00Z